PINC Sector Report – Pharma Monthly Update - December 2011

NEWS ROUNDUP FOR THE MONTH-DECEMBER

DOMESTIC:

- Ranbaxy launches generic version of Lipitor with a profit sharing deal with Teva
- Ranbaxy launches authorized generic version of Caduet
- Ranbaxy signs consent decree with the USFDA
- Ranbaxy Labs' consent decree could engulf multiple facilities
- Dr Reddy's shifts drug discovery focus away from heart diseases
- Dr Reddy's offers VRS to Mexico arm employees
- Dr Reddy's splits its marketing division, Acura to resurrect its ailing domestic business
- Dr Reddy's plans Lipitor generic launch in June
- Dr Reddy's launches pain treatment cream 'Supamove' in India
- Lupin's generic Fortamet launch is prohibited due to grant of Preliminary injunction
- Lupin eyes USD300mn revenues from Japan in the next 2 years
- Lupin to replicate Japan model for expansion in various markets
- Lupin receives final approval for Tricor
- Glenmark to initiate filing for Crofelemer as Salix submits NDA
- Glenmark gets DCGI nod for phase III trials of Crofelemer in India
- Sun Pharma's Dilip Shanghvi buys 3.5% stake in Natco Pharma
- IsZo Capital Management LP, minority shareholder of Taro rejects Sun Pharma's Taro acquisition proposal
- Cadila acquires Biochem Pharmaceuticals
- Orchid Chemicals gets USD1.5mn milestone payment from Merck
- Orchid Chemicals to raise USD100mn ECBs to redeem its outstanding FCCBs
- Clinigene, subsidiary of Biocon enters into collaborative clinical research services agreement with Pacific Biomarkers
- Opto Circuits US arm supplies cardiac devices to Australian soccer clubs

GLOBAL:

- Teva failed to win US clearance for the first OTC emergency contraceptive
- WHO approves Mylan generic HIV drugs for use in developing world
- Mylan wins ruling, overturning generic Doryx antibiotic ban
- Amgen plans to team up with Watson on generics
- GSK to sell non core OTC brands in US and Canada to Prestige Brands Holdings for USD660mn

INDUSTRY:

- 500 drug companies told to pay Rs40bn penalty for over charging.

Source : Equity Bulls

Keywords